CellaVision AB (publ) (CLVSF)

Market Cap	485.50M +17.5%
Revenue (ttm)	76.44M +1.9%
Net Income	13.82M -8.9%
EPS	0.59 -8.9%
Shares Out	n/a
PE Ratio	35.29
Forward PE	26.95
Dividend	0.30 (1.42%)
Ex-Dividend Date	Apr 29, 2026

Volume	100
Open	20.83
Previous Close	20.83
Day's Range	20.83 - 20.83
52-Week Range	13.49 - 20.83
Beta	0.97
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About CellaVision AB

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and Cella...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1994
• Employees: 252
• Stock Exchange: OTCMKTS
• Ticker Symbol: CLVSF

Financial Performance

In 2025, CellaVision AB's revenue was 758.97 million, an increase of 4.94% compared to the previous year's 723.22 million. Earnings were 153.08 million, an increase of 8.78%.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 9, 2026

Data Sources Report a data error